Safe disconnection of 5-fluorouracil elastomeric pumps: The benefit of a closed-system-transfer device designed for cytotoxic drug administration/perfusion
Restricted accessResearch articleFirst published online July, 2023
Safe disconnection of 5-fluorouracil elastomeric pumps: The benefit of a closed-system-transfer device designed for cytotoxic drug administration/perfusion
Occupational exposure to cytotoxic drugs can lead to significant health problems. This study was designed to evaluate the risk of 5-fluorouracil (5-FU) contamination for nurses when disconnecting the infusion line of an elastomeric pump from a non-coring needle, by comparing three configurations: the first one using standard Male and Female Luer lock (Group 1), the second one using a needle-free connector (NFC) and a Male Luer lock (Group 2) and the third one using a closed-system transfer device (CSTD), Qimono® (Group 3).
Methods:
In this in vitro study, 10 elastomeric pumps for each of the three groups were filled with 5-FU and a tissue mimicking the patient’s arm was placed below the connection between the infusion line and the tubing of non-coring needle. After 48 h of infusion, disconnection was performed by a nurse with a wipe soaked in a mix of chlorhexidine and isopropyl alcohol in order to mimic care practices. For each pump, the tissue, the pair of gloves and the wipes used during the disconnection were collected for analysis.
Results:
Median level of overall 5-FU contamination (gloves + wipes + tissues) in group 3 was significantly lower than in group 1 (p = 0.018) and group 2 (p = 0.036). There was no difference between groups 1 and 2. Results per sample type showed no difference in contamination between the three configurations for the gloves as well as for the tissues. Concerning the wipes, the lowest contamination was observed in group 3, representing a mean reduction of 61% compared to group 1 and a mean reduction of 43% compared to group 2.
Conclusion:
The use of Qimono® appears to significantly reduce 5-FU contamination when disconnecting infusion lines of an elastomeric pump unlike NFC and standard Luer lock.
SessinkPJBosRP. Drugs hazardous to healthcare workers. Evaluation of methods for monitoring occupational exposure to cytostatic drugs. Drug Safety1999; 20: 347–359.
2.
MomeniMDanaeiMAskarianM. How do nurses manage their occupational exposure to cytotoxic drugs? A descriptive survey in chemotherapy settings, Shiraz, Iran. Int J Occup Environ Med2013; 4: 102–106.
3.
ZhangXZhengQLvY, et al. Evaluation of adverse health risks associated with antineoplastic drug exposure in nurses at two Chinese hospitals: the effects of implementing a pharmacy intravenous admixture service. Am J Ind Med2016; 59: 264–273.
4.
ValanisBVollmerWMSteeleP. Occupational exposure to antineoplastic agents: self-reported miscarriages and stillbirths among nurses and pharmacists. J Occup Environ Med1999; 41: 632–638.
5.
NdawSDenisFMarsanP, et al. Exposition professionnelle des personnels de santé hospitaliers aux médicaments cytotoxiques. Biométrologie et mesure de la contamination des surfaces – article de revue – INRS, http://www.inrs.fr/media.html?refINRS=TF%20255 (2018, accessed 1 July 2019).
6.
YukiMIshidaTSekineS. Secondary exposure of family members to cyclophosphamide after chemotherapy of outpatients with cancer: a pilot study. Oncol Nurs Forum2015; 42: 665–671.
7.
NdawSRobertARicolfiC, et al. Soignants et médicaments cytotoxiques. Place de la biométrologie dans la maîtrise des risques dans le temps. Bull Epidemiol Hebd2018; 12–13: 252–257.
8.
FransmanWPeelenSHilhorstS, et al. A pooled analysis to study trends in exposure to antineoplastic drugs among nurses. Ann Occup Hyg2007; 51: 231–239.
9.
ViegasSPáduaMVeigaAC, et al. Antineoplastic drugs contamination of workplace surfaces in two Portuguese hospitals. Environ Monit Assess2014; 186: 7807–7818.
10.
SottaniCPorroBImbrianiM, et al. Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicol Lett2012; 213: 107–115.
11.
KoppBSchierlRNowakD. Evaluation of working practices and surface contamination with antineoplastic drugs in outpatient oncology health care settings. Int Arch Occup Environ Health2013; 86: 47–55.
12.
LawsonCCJohnsonCYNassanFL, et al. CE: original research: antineoplastic drug administration by pregnant and nonpregnant nurses: an exploration of the use of protective gloves and gowns. Am J Nurs2019; 119: 28–35.
13.
BoccellinoMPedataPCastigliaL, et al. Doxorubicin can penetrate nitrile gloves and induces apoptosis in keratinocytes cell lines. Toxicol Lett2010; 197: 61–68.
14.
European Parliament. Preventing occupational exposure to cytotoxic and other hazardous drugs. European Policy Recommendations, 2016.
EastyACCoakleyNChengR, et al. Safe handling of cytotoxics: guideline recommendations. Curr Oncol2015; 22: e27–e37.
18.
CDC. NIOSH alert: preventing occupational exposure to antineoplastic and other hazardous drugs in health care settings, www.cdc.gov/niosh/docs/2004-165 (2004, accessed 2 July 2019).
19.
KienlePC. The chapter <800> answer book. Bethesda, MD: American Society of Health-System Pharmacists, 2017.
20.
European Parliament. Directive (EU) 2019/130 of the European Parliament and of the Council of 16 January 2019 amending directive 2004/37/EC on the protection of workers from the risks related to exposure to carcinogens or mutagens at work (text with EEA relevance.), http://data.europa.eu/eli/dir/2019/130/oj/eng (2019, accessed 19 August 2019).
21.
Queruau LamerieTCarrezLDécaudinB, et al. Multiple-test assessment of devices to protect healthcare workers when administering cytotoxic drugs to patients. J Oncol Pharm Pract2012; 18: 191–200.
22.
WickCSlawsonMHJorgensonJA, et al. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health Syst Pharm2003; 60: 2314–2320.
23.
ClarkBASessinkPJ. Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents. J Oncol Pharm Pract2013; 19: 99–104.
24.
BartelSBTylerTGPowerLA. Multicenter evaluation of a new closed system drug-transfer device in reducing surface contamination by antineoplastic hazardous drugs. Am J Health Syst Pharm2018; 75: 199–211.
25.
SimonNVasseurMPinturaudM, et al. Effectiveness of a closed-system transfer device in reducing surface contamination in a new antineoplastic drug-compounding unit: a prospective, controlled, parallel study. PLoS One2016; 11: e0159052.
26.
YoshidaJTeiGMochizukiC, et al. Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Ann Occup Hyg2009; 53: 153–160.
27.
Gómez-ÁlvarezSPorta-OltraBHernández-GrisoM, et al. Evaluación de dos sistemas cerrados en el proceso de elaboración de quimioterapia parenteral. Farm Hosp2016; 40: 36–43.
28.
SessinkPJConnorTHJorgensonJA, et al. Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device. J Oncol Pharm Pract2011; 17: 39–48.
29.
NymanHJorgensonJSlawsonM. Workplace contamination with antineoplastic agents in a new cancer hospital using a closed-system drug transfer device. Hosp Pharm2007; 42: 219–225.
30.
CavalloDUrsiniCLPerniconiB, et al. Evaluation of genotoxic effects induced by exposure to antineoplastic drugs in lymphocytes and exfoliated buccal cells of oncology nurses and pharmacy employees. Mutat Res2005; 587: 45–51.
31.
El-EbiaryAAAbuelfadlAASarhanNI. Evaluation of genotoxicity induced by exposure to antineoplastic drugs in lymphocytes of oncology nurses and pharmacists. J Appl Toxicol2013; 33: 196–201.
32.
CaboutETrouillerJZeitounB, et al. Budget impact analysis of implementing the closed-system transfer device Qimono® during chemotherapy administration in a French hospital. In: ISPOR Europe, Copenhagen, Denmark, 2–6November2019.
33.
Crauste-MancietSDécaudinBEscalupL, et al. GUIDE DE RECOMMANDATIONS DE DISPOSITIFS MÉDICAUX Préparation Administration des Médicaments à Risques pour le Personnel et l’Environnement. Document élaboré à l’initiative d’Europharmat et du GERPAC, 2007.
